Form 4: Erasca Director Varney Granted 96,000 Stock Options

Erasca, Inc. Director Michael David Varney was granted 96,000 stock options with an exercise price of $10.31, vesting monthly over four years.

Summary

• Michael David Varney, a Director of Erasca, Inc. (ERAS), was granted 96,000 stock options.
• The stock options have an exercise price of $10.31 per share.
• The grant date for these options was January 29, 2026.
• The options will vest monthly, with 1/48th of the shares vesting on the 29th day of each month (or the last day of February), starting in February 2026.
• Vesting is contingent upon Mr. Varney's continuous service to Erasca, Inc.
• The options have an expiration date of January 29, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine, slightly positive event. The grant of stock options aligns the director's interests with shareholders, which is generally favorable, but it's a standard compensation practice and not indicative of extraordinary news.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of executive and director compensation, reflecting ongoing commitment and service.

Future Outlook

The vesting schedule, extending over four years, indicates an expectation of continued service from Director Michael David Varney, aligning his long-term incentives with the company's future performance.

Industry Context

Stock option grants are a common component of compensation packages for directors and executives in the biotechnology and pharmaceutical industries, including companies like Erasca, Inc. This practice is widely used to attract, retain, and motivate key personnel by linking their personal wealth to the company's stock performance. StockSavvy.ai notes that such grants are standard practice for aligning management incentives with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across the biotechnology and pharmaceutical sectors, comparable to similar grants observed at companies like Moderna, BioNTech, and Gilead Sciences, which frequently utilize equity-based incentives for their leadership.
• The four-year monthly vesting schedule is typical for long-term incentive plans, similar to those seen in many growth-oriented biotech firms aiming to retain talent and ensure sustained commitment.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can align management's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: While this specific filing is for a director, equity grants are a common tool for employee retention and motivation across the company.

Next Steps

• Michael David Varney's continued service to Erasca, Inc. is required for the monthly vesting of the granted stock options.

Key Dates

Keywords

Erasca, ERAS, stock option, director compensation, equity grant, insider transaction, Form 4